(NASDAQ: PLRX) Pliant Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.51%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.68%.
Pliant Therapeutics's earnings in 2026 is -$92,289,000.On average, 8 Wall Street analysts forecast PLRX's earnings for 2026 to be -$88,046,745, with the lowest PLRX earnings forecast at -$94,666,196, and the highest PLRX earnings forecast at -$83,873,209. On average, 7 Wall Street analysts forecast PLRX's earnings for 2027 to be -$60,510,078, with the lowest PLRX earnings forecast at -$94,666,196, and the highest PLRX earnings forecast at $31,858,816.
In 2028, PLRX is forecast to generate -$52,423,078 in earnings, with the lowest earnings forecast at -$75,854,324 and the highest earnings forecast at -$17,554,858.